Journal of Clinical Investigation · 2023 · 49 citations · 59 references
MedicineNeuroscienceOncologyGene ExpressionMolecular OncologyStem Cell BiologyBrain TumorsCancer Stem Cell BiologyCancer Stem Cell NicheCancer Stem CellsGlioblastomaNeural Stem CellsCancer Stem Cell MarkersCancer Stem Cell NichesCancer Stem-like CellsEmbryonic Stem Cell BiologyGlioblastoma Stem CellsGlioblastoma Tumor BiologyNeural Progenitor DifferentiationRetrovirus Biology
Human endogenous retroviruses (HERVs) are ancestral viral relics that constitute nearly 8% of the human genome. Although normally silenced, the most recently integrated provirus HERV-K (HML-2) can be reactivated in certain cancers. Here, we report pathological expression of HML-2 in malignant gliomas in both cerebrospinal fluid and tumor tissue that was associated with a cancer stem cell phenotype and poor outcomes. Using single-cell RNA-Seq, we identified glioblastoma cellular populations with elevated HML-2 transcripts in neural progenitor-like cells (NPC-like) that drive cellular plasticity. Using CRISPR interference, we demonstrate that HML-2 critically maintained glioblastoma stemness and tumorigenesis in both glioblastoma neurospheres and intracranial orthotopic murine models. Additionally, we demonstrate that HML-2 critically regulated embryonic stem cell programs in NPC-derived astroglia and altered their 3D cellular morphology by activating the nuclear transcription factor OCT4, which binds to an HML-2-specific long-terminal repeat (LTR5Hs). Moreover, we discovered that some glioblastoma cells formed immature retroviral virions, and inhibiting HML-2 expression with antiretroviral drugs reduced reverse transcriptase activity in the extracellular compartment, tumor viability, and pluripotency. Our results suggest that HML-2 fundamentally contributes to the glioblastoma stem cell niche. Because persistence of glioblastoma stem cells is considered responsible for treatment resistance and recurrence, HML-2 may serve as a unique therapeutic target.
59
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom et al. · Cancer Cell · 2010 · 7.7K citations · Full text
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Cyril Neftel, Julie Laffy, Mariella G. Filbin et al. · Cell · 2019 · 2.9K citations · Full text
Medicine, Cancer Biology, Genetics +14
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Steven M. Corsello, Rohith T. Nagari, Ryan D. Spangler et al. · Nature Cancer · 2020 · 883 citations · Full text
Medicine, Oncology, Pharmacology +13
Proteogenomic and metabolomic characterization of human glioblastoma
Liang-Bo Wang, Alla Y. Karpova, Jennifer Kyle et al. · Cancer Cell · 2021 · 692 citations · Full text
Medicine, Cancer Biology, Oncology +17